A telehealth provider may advertise access to GLP-1 treatment, help check your insurance and submit prior-authorization paperwork—but that does not necessarily mean your entire treatment program will be covered.
In many online programs, the clinic membership and the prescription are two separate expenses. Your health plan may cover an FDA-approved medication while leaving you responsible for a monthly telehealth fee. Another plan may cover diabetes treatment with Ozempic or Mounjaro but exclude medications prescribed primarily for weight management. Some plans cover Wegovy or Zepbound only after detailed clinical documentation, while others contain a weight-loss drug exclusion that prevents coverage regardless of whether a clinician considers treatment appropriate.
Coverage remains uneven. In KFF’s 2025 employer survey, 19% of firms with at least 200 workers reported that their largest plan covered GLP-1 medications when used primarily for weight loss. Coverage was more common among employers with at least 5,000 workers, but even in that group, fewer than half reported coverage.
Understanding which part of treatment is covered—and what happens when it is not—can prevent an unexpected bill after enrollment.
CliniqGuide does not provide medical care, diagnose conditions or prescribe medication. Eligibility for prescription treatment depends on evaluation by a licensed healthcare professional.
Key takeaways
- Insurance coverage for the prescription does not automatically include the telehealth membership. Many online clinics charge separately for provider access, care coordination or coaching.
- A prior-authorization requirement is not the same as a weight-loss drug exclusion. Prior authorization provides a pathway to approval; an exclusion may mean the plan does not cover obesity medication as a benefit.
- The condition being treated matters. Ozempic and Mounjaro are FDA-approved for type 2 diabetes, while Wegovy and Zepbound have weight-management indications. Zepbound also has an indication for certain adults with obesity and moderate-to-severe obstructive sleep apnea, while Wegovy has additional cardiovascular and liver-related indications.
- Insurance-support services can check benefits, collect documentation and submit paperwork, but they cannot guarantee coverage or override a plan exclusion.
- Manufacturer programs can substantially reduce cash prices for eligible patients, but the terms, doses, formulations and eligibility rules vary—and may change or expire.
- Many telehealth prescriptions can be sent to a local pharmacy, but patients should confirm that the clinic supports local fulfillment and that the pharmacy is in network.
What part of online GLP-1 treatment might insurance cover?
“Online GLP-1 treatment” commonly combines several services under one website or membership. Each component may be billed differently.
| Treatment component | Could insurance cover it? | What to verify |
| Telehealth intake or consultation | Sometimes | Whether the clinician or affiliated practice is in network |
| Monthly clinic membership | Often self-pay, but policies vary | Whether the fee is billed to insurance or charged directly |
| FDA-approved prescription medication | Possibly | Formulary status, indication, prior authorization and deductible |
| Compounded medication | Do not assume coverage | Whether the plan reimburses it and which pharmacy prepares it |
| Laboratory testing | Sometimes | Whether the lab is in network and whether testing is medically necessary |
| Nutrition or behavioral support | Possibly | Provider network status and visit limits |
| Medication delivery | Depends | Mail-order benefits, shipping fees and pharmacy network rules |
| Local pharmacy dispensing | Possibly | Whether the pharmacy and medication are covered by the plan |
Prescription drug coverage is usually administered through a health plan’s pharmacy benefit and drug formulary. A formulary is the list of medications the plan covers, often with separate tiers, copays and utilization-management rules. Marketplace guidance advises members to consult their formulary and use their plan’s drug-exception process when a prescribed medication is not ordinarily covered.
The clinic membership is different. It may pay for clinician access, messaging, insurance coordination, nutrition support or ongoing monitoring. Even when the prescription is covered, the membership may remain a recurring direct charge.
For example, Ro currently presents its Body membership and medication as separate costs. Its published pricing starts at $39, with ongoing membership advertised as low as $74 per month under an annual prepaid plan; its month-to-month price is currently listed as $149. Medication is not included.
Mochi Health currently advertises a $39 new-member promotional first month, increasing to $79 per month afterward. Its site states that medication and diagnostic services are not included in that membership price. Mochi also says that coverage for its membership, medication and other services depends on the individual insurance plan.
These prices and terms should be rechecked before publication or enrollment.
Weight-loss medication exclusions: when prior authorization cannot solve the problem
A weight-loss drug exclusion generally means that the health plan does not include medications used primarily for weight reduction within its covered pharmacy benefit.
This differs from a drug simply being non-preferred or requiring prior authorization.
A drug exclusion may mean:
- Anti-obesity medications are omitted as a benefit category
- The plan covers a GLP-1 only for diabetes or another covered indication
- The employer sponsoring the plan has chosen not to cover weight-management drugs
- A particular formulation or brand is excluded
- The member must use another employer-sponsored weight-management benefit instead
Prior authorization means:
The medication may be covered, but the insurer requires the patient and prescriber to demonstrate that the plan’s criteria are met before it will pay.
The National Association of Insurance Commissioners defines prior authorization as a process requiring a provider to obtain health-plan approval before a service or prescription is covered. Without approval, the plan may decline payment.
This distinction matters because submitting more paperwork does not necessarily overcome a contractual exclusion. An insurance-support team can verify whether an exclusion exists and may help request an exception or appeal where one is available, but it cannot rewrite the benefits selected by an employer or insurer.
Ask the plan specifically:
“Are FDA-approved anti-obesity medications excluded under my pharmacy benefit, or is this particular medication covered subject to prior authorization?”
That wording is more useful than asking only whether “GLP-1s are covered,” because the same plan may cover one GLP-1 for type 2 diabetes while excluding another when prescribed for weight management.
Common GLP-1 insurance coverage requirements
Requirements vary by insurer, employer, medication and indication. A prior-authorization form may request documentation of:
- Current and previous body mass index
- An obesity or overweight diagnosis
- Weight-related medical conditions
- The medication’s intended use
- Previous weight-management treatment
- Participation in a nutrition, physical-activity or behavioral program
- Previous medications tried and the outcome
- Contraindications to preferred alternatives
- Relevant clinical notes or laboratory results
- A plan for follow-up and continued treatment
Plans may also impose step therapy, quantity limits or continuation criteria. Medicare’s general prescription-drug guidance describes step therapy as a requirement to try a less expensive or preferred treatment before the plan covers a higher-cost option.
Approval may need to be renewed periodically. A patient who initially receives coverage can later face a new authorization requirement after changing employers, changing insurance plans, switching medications or entering a new benefit year.
A previous approval therefore should not be treated as permanent.
What an insurance-support service actually does
“Insurance support,” “insurance concierge” and “coverage assistance” are broad marketing terms. The practical value depends on which services are included.
1. Benefit verification
The service contacts the insurer or pharmacy-benefit manager to determine:
- Whether the medication appears on the formulary
- Whether prior authorization is required
- Whether step therapy applies
- Which formulations or pharmacies are covered
- The estimated copay or coinsurance
- Whether a deductible applies
Benefit verification is useful, but it is not a guarantee. The final claim can still process differently based on eligibility, accumulated deductible, the diagnosis submitted, the pharmacy used or changes to the formulary.
2. Prior-authorization preparation
If authorization is required, a clinic may collect clinical information and prepare the insurer’s form. The prescribing clinician must generally provide or approve the medical justification.
Supporting information might include:
- Diagnosis and BMI documentation
- Relevant medical history
- Previous treatment attempts
- Clinical notes
- A letter of medical necessity
- Evidence that the requested medication meets the plan’s criteria
3. Submission and status follow-up
Some services submit the authorization and communicate with the insurer until a decision is issued. Others only tell the patient what documentation is needed.
This difference is worth confirming before paying a membership fee.
4. Denial and appeal support
A more comprehensive service may:
- Obtain the denial reason
- Correct missing or inaccurate information
- Submit additional clinical records
- Request a formulary or utilization-management exception
- Prepare an appeal or letter of medical necessity
- Help the patient and clinician identify an alternative covered drug
HealthCare.gov explains that insured patients may have access to internal appeals and, in qualifying situations, an independent external review. Exact rights and deadlines depend on the plan and denial.
What insurance support cannot do
An insurance-support service cannot:
- Guarantee approval
- Guarantee a particular copay
- Force a plan to cover an excluded benefit
- Change an employer’s pharmacy benefit
- Substitute paperwork for medical eligibility
- Prescribe medication without a clinical evaluation
- Ensure that a pharmacy has the medication in stock
- Make a manufacturer offer available to someone who does not satisfy its terms
Ro and Mochi Health: two insurance-support examples
The following comparison reflects information published by the providers themselves. It should be treated as a description of their current stated services rather than independent proof of approval rates or service quality.
| Insurance feature | Ro | Mochi Health |
| Standalone coverage check | Offers a free GLP-1 insurance coverage checker | Insurance details are generally collected through enrollment |
| What the initial check covers | Ro currently says its report includes coverage information for Ozempic, Wegovy and Zepbound pens and notes whether prior authorization is required | Mochi says its team verifies coverage based on the patient’s insurer, plan and employer |
| Does the initial check prescribe treatment? | No. Ro says the free checker does not submit a treatment request or write a prescription | A prescription depends on a subsequent clinical evaluation |
| Prior-authorization support | Ro says its insurance concierge submits paperwork when authorization is required | Mochi says its team supports prior authorizations and letters of medical necessity |
| Local pharmacy option | Ro says that, when covered, the prescription is sent to a pharmacy | Mochi states that eligible brand-name prescriptions may be sent to a local pharmacy or certain delivery services |
| Membership and medication | Separate charges | Membership, medication and diagnostic services may be separate |
| Current membership pricing | $39 to start; as low as $74/month with annual prepayment; $149 month-to-month | Promotional $39 first month, then $79/month at current advertised terms |
Sources: Ro’s insurance checker, insurance-support and pricing pages; Mochi’s pricing, FAQ and provider-comparison materials.
Ro’s free checker is primarily a benefit-verification tool. Ro says its specialists contact the insurer and prepare a report but do not submit a treatment request or prescribe medication at that stage. Patients who enroll in the treatment program may receive prior-authorization assistance if a clinician prescribes an appropriate medication.
Mochi says its virtual medical-assistant team contacts insurance companies, helps ensure documentation is available and supports prior authorizations and letters of medical necessity. Its published materials also state that coverage depends on the carrier, plan and employer.
Neither model guarantees that a medication will be approved. Consumers should also verify whether insurance support continues through appeals and renewal authorizations or ends after the first submission.
Can an online GLP-1 prescription be filled at a local pharmacy?
Often, yes—but it depends on the provider, medication, state, insurance network and pharmacy.
A telehealth clinician may electronically send an FDA-approved brand-name prescription to:
- A local retail pharmacy
- An insurer’s preferred or specialty pharmacy
- A mail-order pharmacy
- A manufacturer-affiliated pharmacy
- A pharmacy selected by the telehealth provider
Ro states that approved insured prescriptions are sent to a pharmacy. Mochi describes local pharmacy pickup as an option for certain brand-name prescriptions, alongside delivery programs such as NovoCare or LillyDirect.
Local fulfillment can be useful when:
- The pharmacy is in the patient’s insurance network
- The patient wants to check inventory directly
- A manufacturer savings card can be processed at retail
- Refrigerated delivery is inconvenient
- The patient wants to use an established pharmacist
However, a prescription being sent successfully does not establish that it is covered or in stock.
Before enrolling, ask:
- Can I choose my pharmacy?
- Will you send the prescription to an in-network local pharmacy?
- Can I transfer it if the first pharmacy is out of stock?
- Do you require use of an affiliated mail-order pharmacy?
- Can the pharmacy process my insurance and manufacturer savings card?
- What happens if my dose is unavailable?
Compounded prescriptions may follow a different fulfillment process and may be restricted to the clinic’s affiliated compounding pharmacy.
Insurance, manufacturer savings and cash pay compared
| Payment pathway | Potential advantage | Important limitation |
| Insurance coverage | May produce the lowest recurring medication cost | May require PA, step therapy, deductible or renewal |
| Commercial insurance plus manufacturer card | May reduce an eligible copay further | Savings limits and eligibility rules apply |
| Manufacturer self-pay program | Predictable price without waiting for insurance approval | Purchase may not count toward the insurance deductible or out-of-pocket maximum |
| Telehealth cash-pay program | Convenient and may combine care and medication | Confirm whether the product is branded or compounded and whether dosing changes the price |
| Retail cash price or discount card | Allows comparison among pharmacies | Price can vary and may not count toward insurance spending limits |
| Medicare or Medicaid | Potentially low cost for covered patients | Eligibility, indication and state or program rules apply |
Manufacturer savings cards
Commercially insured patients may qualify for manufacturer copay assistance. These programs typically have maximum monthly or annual savings limits, and the advertised “as little as” price does not mean every eligible patient will pay that amount.
For example:
- Novo Nordisk currently states that commercially insured patients with Wegovy coverage may pay as little as $25 per month, subject to a maximum savings amount. Its commercial copay offer excludes people enrolled in Medicare, Medicaid and several other government-funded programs.
- Lilly currently advertises Zepbound for as little as $25 for eligible commercially insured patients whose plans cover the relevant single-dose pen. The card has maximum savings limits and excludes enrollment in Medicare, Medicaid and other listed government-funded programs.
A savings card may reduce the patient’s cost after insurance processes the claim, but it does not create insurance coverage where none exists.
Manufacturer self-pay options
Manufacturers increasingly offer direct cash-pay pricing through designated pharmacies or savings arrangements.
As of July 29, 2026:
- NovoCare advertises eligible new Wegovy patients a price of $199 for each of the first two monthly fills at the 0.25 mg and 0.5 mg doses through December 31, 2026. The current published price then increases to $349 per month for listed standard injection doses, with a separate price for Wegovy HD.
- Lilly currently advertises the Zepbound KwikPen or vial starting at $299 per month. Published KwikPen terms list different prices at higher doses, with restrictions and an offer expiration of December 31, 2026.
These are examples, not permanent list prices. The eligible formulation, dose, pharmacy, refill timing and insurance status can all affect the final amount.
Purchases made under a manufacturer self-pay offer generally operate outside insurance. Novo Nordisk’s current terms state that patients using its Wegovy self-pay pathway may not seek insurance reimbursement or count the purchase toward an insurance deductible or out-of-pocket limit.
Telehealth cash-pay options
A clinic may offer:
- FDA-approved branded medication at a manufacturer-supported cash price
- Compounded semaglutide or tirzepatide
- Non-GLP-1 prescription medication
- A bundled care-and-medication subscription
- A separate membership plus medication charge
Always determine exactly what the advertised price includes.
A price described as “starting at $199” may apply only to:
- An introductory dose
- A particular formulation
- A prepaid commitment
- The medication without membership
- New customers
- One state or pharmacy
- A compounded rather than FDA-approved product
Compounded medication is not the same as an FDA-approved brand
Compounded semaglutide or tirzepatide should not be described as generic Wegovy or generic Zepbound. Compounded medications are not FDA approved and are not reviewed by FDA in the same way for safety, effectiveness and manufacturing quality.
FDA states that a compounded drug may be appropriate when a patient’s medical need cannot be met by an FDA-approved drug or when the approved product is not commercially available. FDA has also warned about unapproved, fraudulent and improperly marketed GLP-1 products, including products with false pharmacy information.
Before accepting a compounded prescription, ask:
- Why is a compounded preparation being recommended?
- Which licensed pharmacy will prepare it?
- What active ingredient and concentration will be dispensed?
- How will the dose be measured?
- Is the pharmacy authorized to ship into my state?
- How are adverse events and temperature excursions handled?
- Is an FDA-approved option medically and financially available?
Do not purchase products labeled “research use only,” “not for human consumption” or supplied without a prescription and licensed clinical evaluation.
Commercial insurance, Medicare and Medicaid follow different rules
Commercial and employer-sponsored insurance
Employer plans frequently determine whether weight-loss drugs are included as a benefit. Two people with insurance cards from the same national insurer may therefore receive different coverage because their employers selected different formularies or exclusions.
Coverage can also change at renewal. A drug covered this year may be removed, moved to a different tier or subjected to stricter authorization criteria the following year.
Check both:
- The insurer’s current formulary
- The employer’s summary plan description or pharmacy-benefit documents
Medicare
Medicare coverage changed materially in 2026.
Beginning July 1, 2026, the temporary nationwide Medicare GLP-1 Bridge began providing certain eligible Medicare Part D beneficiaries with access to specified weight-management medications for a $50 monthly copay. The current program includes Foundayo, Wegovy injections or tablets and the Zepbound KwikPen—not Zepbound single-dose pens or vials. The demonstration is scheduled to run through December 31, 2027.
The Bridge has specific BMI and comorbidity requirements. Current Medicare guidance says eligibility may include:
- BMI of at least 35
- BMI of at least 30 with specified conditions such as uncontrolled hypertension, certain heart failure or stage 3a or higher chronic kidney disease
- BMI of at least 27 with specified conditions such as prediabetes, previous heart attack or stroke, or symptomatic peripheral artery disease
A provider must prescribe an eligible drug, complete prior authorization when requested and certify participation in an appropriate lifestyle program. People already receiving Part D coverage for a GLP-1 or seeking treatment for certain other coverable indications may follow different rules.
The $50 payment under the Bridge does not count toward the Part D deductible or out-of-pocket limit because the demonstration operates outside the regular Part D payment flow.
Because this is a new and temporary program, its medications, criteria and operational details should be reverified immediately before publication.
Medicaid
Medicaid pharmacy benefits and obesity-drug policies vary by state. All states provide outpatient prescription coverage to most eligible enrollees, but states retain significant control over preferred drugs, exclusions and prior-authorization rules.
CMS’s voluntary BALANCE model is designed to expand access to selected GLP-1 medications in participating state Medicaid programs, but coverage depends on state and manufacturer participation.
Patients should check their state Medicaid formulary rather than relying on a national telehealth provider’s general statement about insurance acceptance.
How online GLP-1 treatment usually works when using insurance
1. Online intake
The patient provides information about medical history, current medication, weight history, allergies, previous treatment and insurance.
Completing an intake does not guarantee a prescription.
2. Clinical evaluation
A licensed clinician reviews whether treatment may be medically appropriate and whether additional information, testing or consultation is needed.
3. Medication selection
The clinician considers medical history, FDA indications, contraindications, adverse-effect risks, patient preferences and practical access. Insurance coverage may influence the feasible options, but formulary status should not replace clinical judgment.
4. Benefit investigation
The clinic, patient or pharmacy checks the plan’s formulary, estimated cost and authorization rules.
5. Prior authorization
If required, the prescriber and support team submit documentation.
6. Coverage decision
The insurer may:
- Approve the medication
- Request more information
- Require another medication first
- Approve only a specific formulation or pharmacy
- Deny the request
- State that weight-loss medications are excluded
7. Pharmacy fulfillment
An approved prescription is sent to an eligible local, mail-order, specialty or manufacturer-affiliated pharmacy.
8. Follow-up
Ongoing care should include assessment of tolerability, side effects, dose changes, medication interactions and whether treatment remains appropriate.
What to do after a denial
Start by obtaining the exact reason. A denial may result from:
- Missing documentation
- Incorrect diagnosis coding
- Failure to satisfy BMI or comorbidity criteria
- Lack of a required lifestyle-program history
- Step-therapy requirements
- Use of a non-preferred medication
- A formulary exclusion
- A complete weight-loss drug exclusion
- An out-of-network pharmacy
- A mismatch between the requested drug and FDA-approved indication
Then ask whether the decision can be addressed through:
- Corrected prior authorization
- Additional clinical documentation
- A letter of medical necessity
- A step-therapy exception
- A formulary exception
- An internal appeal
- An external review
- A different covered medication
- A manufacturer or cash-pay option
An appeal is most useful when the plan covers the benefit but disputes whether its criteria have been met. It is less likely to succeed when the governing plan document explicitly excludes all medications used for weight loss, although patients should still ask whether an exception process exists.
Safety and eligibility remain separate from coverage
Insurance approval does not establish that a medication is appropriate for an individual patient. Conversely, a clinician may consider a medication appropriate even when the insurer refuses to cover it.
Wegovy and Zepbound commonly cause gastrointestinal effects such as nausea, diarrhea, vomiting, constipation and abdominal symptoms. Both carry boxed warnings concerning thyroid C-cell tumors observed in animals, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Their prescribing information includes additional warnings and precautions that require individualized review.
A legitimate online program should collect enough information to evaluate contraindications, medication interactions and relevant medical history. It should also provide a clear way to contact a clinician about side effects and explain when urgent in-person care is appropriate.
Coverage assistance should never replace medical assessment.
Red flags when comparing online GLP-1 programs
Be cautious when a provider or seller:
- Guarantees a prescription or insurance approval
- Claims every insurance plan covers GLP-1 medication
- Refuses to disclose whether membership is billed separately
- Advertises a monthly price without saying whether medication is included
- Does not identify the prescribing clinician or affiliated medical practice
- Will not identify the dispensing pharmacy
- Requires payment before explaining recurring charges
- Does not describe prior-authorization or appeal support clearly
- Sells products labeled for research use
- Claims that compounded medication is FDA approved
- Calls compounded semaglutide or tirzepatide a generic equivalent of Wegovy or Zepbound
- Provides medication without an adequate medical evaluation
- Has no clear follow-up or adverse-event process
- Makes cancellation unusually difficult to understand
- Claims that coverage is confirmed before receiving a formal insurer decision
Who may prefer each payment pathway?
Insurance-supported treatment may appeal to people who:
- Have confirmed anti-obesity medication coverage
- Expect a manageable copay after authorization
- Want the prescription processed through a local in-network pharmacy
- Need assistance compiling prior-authorization documentation
- Are prepared for possible delays or renewals
- Want covered medication spending to count toward insurance cost-sharing limits
Manufacturer cash-pay treatment may appeal to people who:
- Have a plan exclusion
- Have a deductible or coinsurance that makes insurance more expensive
- Qualify for a direct manufacturer price
- Prefer predictable medication costs
- Understand that the purchase may occur outside insurance
- Can afford ongoing treatment if the offer changes or expires
A telehealth cash-pay program may appeal to people who:
- Want bundled remote care and medication access
- Value predictable billing
- Do not have usable insurance coverage
- Understand whether the medication is brand-name or compounded
- Have verified the pharmacy, cancellation rules and ongoing price
Online treatment may not suit people who:
- Need urgent or complex in-person evaluation
- Cannot obtain appropriate monitoring through telehealth
- Prefer care coordinated entirely through an existing primary-care clinician
- Are unable to sustain the likely long-term cost
- Cannot identify the clinician or pharmacy involved
- Are being offered medication without a meaningful clinical review
Questions to ask before enrolling
Insurance and authorization
- Do you check whether my plan excludes weight-loss medications?
- Is a coverage check included before I pay for membership?
- Will you submit prior authorization or only tell me that it is required?
- Do you handle appeals, renewals and letters of medical necessity?
- What documentation will you need from my previous clinicians?
- What happens if the insurer asks me to complete step therapy?
- Can you determine whether my deductible applies?
- Will you tell me the insurer’s exact denial reason?
Membership and pricing
- Is the telehealth membership billed to insurance or charged directly?
- Is medication included in the advertised price?
- What will I pay after the introductory period?
- Does the price change with the dose?
- Are consultations, labs, shipping and follow-up included?
- Is prepayment required?
- What happens to prepaid fees if I am not prescribed medication?
- How do I cancel, and when does the next charge occur?
Medication and pharmacy
- Which FDA-approved medications can your clinicians prescribe?
- Do you offer compounded preparations?
- Which pharmacy will fill my prescription?
- Can I choose a local in-network pharmacy?
- Can the prescription be transferred if the medication is unavailable?
- Can the pharmacy process a manufacturer savings card?
- How will I know whether I am receiving an FDA-approved or compounded product?
- Who should I contact about side effects or a missed dose?
The bottom line
Insurance can cover a GLP-1 medication prescribed through an online clinic, but coverage is determined primarily by the patient’s health plan, employer benefit, diagnosis, formulary and authorization criteria—not by the fact that treatment is provided through telehealth.
The most important first step is identifying whether the plan contains a true weight-loss drug exclusion or merely requires prior authorization. From there, compare the full cost of the membership, medication, labs and pharmacy fulfillment rather than focusing on the lowest advertised monthly price.
Insurance-support services can reduce administrative work and make coverage rules easier to understand. Their practical value is highest when they perform benefit verification, submit complete prior-authorization documentation, follow up on requests and assist with appeals. They cannot guarantee approval or overcome every exclusion.
When insurance is unavailable, manufacturer self-pay programs and transparent cash-pay clinics may offer alternatives. Those options still require careful review of the medication, pharmacy, recurring price, offer expiration and clinical follow-up.
The right route depends on medical eligibility, insurance terms, treatment preferences and what the patient can reasonably sustain over time.
